Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 4/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 4/20 | 0.43 |
| ▸ | CTSD | P07339 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6534564 | 1.00 | REN (0.44) | RENELANEBACE1CTSDCASP3 | |
| SCHEMBL2801278 | 0.91 | CASP3 (0.47) | RENELANECTSDCASP3 | |
| SCHEMBL5346824 | 0.89 | ATM (0.45) | ELANE | |
| SCHEMBL948864 | 0.89 | ATM (0.45) | ELANE | |
| SCHEMBL12273287 | 0.87 | REN (0.41) | REN | |
| SCHEMBL4460244 | 0.84 | ELANE (0.51) | RENELANEBACE1CASP3 | |
| SCHEMBL2802686 | 0.77 | ATM (0.48) | — | |
| SCHEMBL5494468 | 0.77 | CTSD (0.51) | RENCTSDCASP3 | |
| SCHEMBL12247706 | 0.76 | MAPT (0.59) | — | |
| SCHEMBL8231730 | 0.76 | SYK (0.46) | RENCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-20 | — | — | US | disclosed |
| US-7288624-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-30 | — | — | US | disclosed |
| US-20020099042-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-25 | — | — | US | disclosed |
| US-6420522-B1 | ENZYME INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099042-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1RN | REN 184/4885ELANE 135/4885BACE1 12/4885 |
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | REN 192/4885ELANE 140/4885BACE1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.